Barclays PLC Blueprint Medicines Corp Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Barclays PLC holds 171,196 shares of BPMC stock, worth $16.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

171,196

Previous 171,196 -0.0%

Holding current value

$16.2 Million

Previous $15.8 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$84.1 - $120.5 $9.92 Million - $14.2 Million	117,993 Added 221.78%	171,196 $15.8 Million
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $1.04 Million - $1.33 Million	-12,192 Reduced 18.64%	53,203 $5.74 Million
Q1 2024 May 15, 2024	SELL	$73.17 - $99.79 $5.93 Million - $8.09 Million	-81,098 Reduced 55.36%	65,395 $6.2 Million
Q4 2023 Feb 15, 2024	BUY	$43.96 - $92.84 $876,914 - $1.85 Million	19,948 Added 15.76%	146,493 $13.5 Million
Q3 2023 Nov 07, 2023	BUY	$46.9 - $66.0 $1.04 Million - $1.47 Million	22,198 Added 21.27%	126,545 $6.36 Million
Q2 2023 Aug 03, 2023	BUY	$42.2 - $66.37 $124,363 - $195,592	2,947 Added 2.91%	104,347 $6.59 Million
Q1 2023 May 04, 2023	SELL	$37.97 - $50.0 $865,184 - $1.14 Million	-22,786 Reduced 18.35%	101,400 $4.56 Million
Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $2.07 Million - $3.35 Million	50,317 Added 68.12%	124,186 $5.44 Million
Q3 2022 Nov 03, 2022	BUY	$49.93 - $77.7 $2.42 Million - $3.76 Million	48,428 Added 190.35%	73,869 $4.87 Million
Q2 2022 Aug 12, 2022	SELL	$45.23 - $70.15 $109,773 - $170,254	-2,427 Reduced 8.71%	25,441 $1.28 Million
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $2.42 Million - $4.92 Million	-44,692 Reduced 61.59%	27,868 $1.78 Million
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $2.68 Million - $3.3 Million	28,481 Added 64.61%	72,560 $7.77 Million
Q3 2021 Nov 09, 2021	BUY	$80.98 - $109.47 $2.69 Million - $3.64 Million	33,272 Added 307.87%	44,079 $4.53 Million
Q2 2021 Aug 13, 2021	SELL	$82.78 - $101.0 $3.71 Million - $4.53 Million	-44,861 Reduced 80.59%	10,807 $949,000
Q1 2021 May 13, 2021	BUY	$90.71 - $108.28 $2.08 Million - $2.48 Million	22,901 Added 69.89%	55,668 $5.41 Million
Q4 2020 Feb 11, 2021	SELL	$92.08 - $124.48 $694,283 - $938,579	-7,540 Reduced 18.71%	32,767 $3.68 Million
Q3 2020 Nov 12, 2020	SELL	$66.45 - $92.7 $5.45 Million - $7.6 Million	-81,943 Reduced 67.03%	40,307 $3.74 Million
Q2 2020 Aug 12, 2020	BUY	$57.09 - $79.27 $3.71 Million - $5.15 Million	64,912 Added 113.21%	122,250 $9.54 Million
Q1 2020 May 13, 2020	SELL	$48.11 - $82.22 $2.46 Million - $4.21 Million	-51,190 Reduced 47.17%	57,338 $3.35 Million
Q4 2019 Feb 10, 2020	BUY	$66.73 - $82.59 $5.37 Million - $6.65 Million	80,468 Added 286.77%	108,528 $8.69 Million
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $504,978 - $702,467	-6,927 Reduced 19.8%	28,060 $2.06 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $530,076 - $704,942	7,208 Added 25.95%	34,987 $3.3 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $1.19 Million - $2.12 Million	24,436 Added 730.96%	27,779 $2.22 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $1.25 Million - $2.04 Million	-27,471 Reduced 89.15%	3,343 $181,000
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $636,876 - $846,717	10,811 Added 54.05%	30,814 $2.41 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $484,388 - $803,976	7,946 Added 65.9%	20,003 $1.27 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $205,916 - $289,289	2,810 Added 30.39%	12,057 $1.11 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $398,283 - $559,153	6,331 Added 217.11%	9,247 $698,000
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $123,550 - $203,157	2,916	2,916 $203,000

Others Institutions Holding BPMC

# of Institutions

350

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.65B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account